The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.

ABSTRACT:

Background

There are currently no validated criteria that entirely explain or predict response to methotrexate (MTX) treatment in rheumatoid arthritis (RA). We tried to identify the connection between three variants (RFC1 G80A (rs1051266), TYMS 2R/3R (rs34743033), and ATIC C347G (rs2372536)) in the folate pathway of MTX metabolism and the response to MTX monotherapy in a cohort of RA cases.

Methods

A prospective study on 100 RA patients on MTX monotherapy was performed. Disease activity was measured at the start of treatment and 6 months after treatment with MTX. The patients were then split into two groups: those who responded to the treatment and those who did not. The molecular genetic study for the RFC1 (G80A) variant was employed via the PCR-restriction fragment length

SUBMITTER: Nomair AM 

PROVIDER: S-EPMC10876746 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature